87 research outputs found

    «Ridges on the floors of Hell»: traces ou palimpsestes dans le désert de The dead heart

    Get PDF
    The Dead Heart is American author Douglas Kennedy’s first novel. It was first translated into French in 1997 as Cul-de-sac . It was this translation that made Kennedy a household name in France and that gave The Dead Heart its identity as a roman noir. In the space of just 20 years the novel has been translated twice into French and adapted twice more, as a film and now as a graphic novel. Elsewhere, we have analyzed this trajectory from the perspective of retranslation and the ostensible differences between the two translation Skopoi, and the use of paratextual branding to target specific reading publics. Focusing on the graphic novel allows us here to go beyond the problematics of translation and to broaden the scope of our study of textual adaptation. It also allows us to reassess the originality of the source text

    Fathom

    Get PDF
    [Extract] Terrestrial, bipedal, air breathing, and poorly waterproofed, how can humans fathom the bottom of the sea? This article was composed by an anthropologist, a cultural theorist, a philosopher, a coastal geographer, a cultural geographer, a feminist studies scholar, an artist, a spatial scientist, an ecocritic, a free diver, an STS scholar, a spear fisher, a biologist, a marine ecologist, a poet, a dancer, and a swimmer. (If the math does not add up, we remind you that we are always more than one.) Our insights emerged from a one-day workshop at Clovelly Beach in Sydney, Australia, on land and in the water, where we shared our perspectives and practices in researching ocean environments. Our collaboration is an experiment in multidisciplinary practice-based inquiry, where differences and tensions need not preclude collaborative understanding. In this article we combine emerging critical ocean studies and blue humanities perspectives to propose fathoming as a vital, embodied practice that gathers technoscientific acts of measurement together with practices of immersion, imagination, and speculation. Through collaborative multi-situated inquiry1 we learn new things not only about the sea but also about the limits of epistemological mastery and the rewards of knowing with

    Algorithmic iteration for computational intelligence

    Get PDF
    Machine awareness is a disputed research topic, in some circles considered a crucial step in realising Artificial General Intelligence. Understanding what that is, under which conditions such feature could arise and how it can be controlled is still a matter of speculation. A more concrete object of theoretical analysis is algorithmic iteration for computational intelligence, intended as the theoretical and practical ability of algorithms to design other algorithms for actions aimed at solving well-specified tasks. We know this ability is already shown by current AIs, and understanding its limits is an essential step in qualifying claims about machine awareness and Super-AI. We propose a formal translation of algorithmic iteration in a fragment of modal logic, formulate principles of transparency and faithfulness across human and machine intelligence, and consider the relevance to theoretical research on (Super)-AI as well as the practical import of our results

    Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

    No full text
    BACKGROUND Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively. METHODS We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral standard-of-care antibiotics for primary or recurrent C. difficile infection. Participants received an infusion of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), or placebo; actoxumab alone (10 mg per kilogram) was given in MODIFY I but discontinued after a planned interim analysis. The primary end point was recurrent infection (new episode after initial clinical cure) within 12 weeks after infusion in the modified intention-to-treat population. RESULTS In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, −10.1 percentage points; 95% confidence interval [CI], −15.9 to −4.3; P<0.001; MODIFY II: 16% [62 of 395] vs. 26% [97 of 378]; adjusted difference, −9.9 percentage points; 95% CI, −15.5 to −4.3; P<0.001) and was significantly lower with actoxumab plus bezlotoxumab than with placebo (MODIFY I: 16% [61 of 383] vs. 28% [109 of 395]; adjusted difference, −11.6 percentage points; 95% CI, −17.4 to −5.9; P<0.001; MODIFY II: 15% [58 of 390] vs. 26% [97 of 378]; adjusted difference, −10.7 percentage points; 95% CI, −16.4 to −5.1; P<0.001). In prespecified subgroup analyses (combined data set), rates of recurrent infection were lower in both groups that received bezlotoxumab than in the placebo group in subpopulations at high risk for recurrent infection or for an adverse outcome. The rates of initial clinical cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotoxumab, and 80% with placebo; the rates of sustained cure (initial clinical cure without recurrent infection in 12 weeks) were 64%, 58%, and 54%, respectively. The rates of adverse events were similar among these groups; the most common events were diarrhea and nausea. CONCLUSIONS Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo. The addition of actoxumab did not improve efficacy. (Funded by Merck; MODIFY I and MODIFY II ClinicalTrials.gov numbers, NCT01241552 and NCT01513239.

    Translating national allegories: the case of crime fiction

    No full text
    Abstract not availableAlistair Rolls, Marie-Laure Vuaille-Barcan and John West-Soob

    Early molecular diagnosis of acute Chagas disease after transplantation with organs from Trypanosoma cruzi-infected donors

    Get PDF
    Organ transplantation (TX) is a novel transmission modality of Chagas disease. The results of molecular diagnosis and characterization of Trypanosoma cruzi acute infection in naĂŻve TX recipients transplanted with organs from infected deceased donors are reported. Peripheral blood and cerebrospinal fluid samples from the TX recipients of organs from infected donors were prospectively and sequentially studied for detection of T. cruzi by means of kinetoplastid DNA polymerase chain reaction (kDNA-PCR). In positive blood samples, a PCR algorithm for identification of T. cruzi Discrete Typing Units (DTUs) and quantitative real-time PCR (qPCR) to quantify parasitic loads were performed. Minicircle signatures of T. cruzi infecting populations were also analyzed using restriction fragment length polymorphism (RFLP)-PCR. Eight seronegative TX recipients from four infected donors were studied. In five, the infection was detected at 68.4 days post-TX (36–98 days). In one case, it was transmitted to two of three TX recipients. The comparison of the minicircle signatures revealed nearly identical RFLP-PCR profiles, confirming a common source of infection. The five cases were infected by DTU TcV. This report reveals the relevance of systematic monitoring of TX recipients using PCR strategies in order to provide an early diagnosis allowing timely anti-trypanosomal treatment.Fil: Cura, Carolina InĂ©s. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂ­a GenĂ©tica y BiologĂ­a Molecular; ArgentinaFil: Lattes, R.. Instituto de Nefrologia de Buenos Aires; ArgentinaFil: Nagel, C.. Universidad Favaloro; ArgentinaFil: Gimenez, M. J.. Hospital Universitario y PolitĂ©cnico LA FE. Servicio de MicrobiologĂ­a; EspañaFil: Blanes, M.. Hospital Universitario y PolitĂ©cnico LA FE. Area MĂ©dica. Unidad de Enfermedades Infecciosas; EspañaFil: Calabuig, E.. Hospital Universitario y PolitĂ©cnico LA FE. Area MĂ©dica. Unidad de Enfermedades Infecciosas; EspañaFil: Iranzo, A.. Hospital Universitario y PolitĂ©cnico LA FE. Servicio de MicrobiologĂ­a; EspañaFil: Barcan, L. A.. Hospital Italiano de Buenos Aires; ArgentinaFil: Anders, M.. Hospital AlemĂĄn; ArgentinaFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂ­a GenĂ©tica y BiologĂ­a Molecular; Argentin
    • 

    corecore